Finance

Lists
Why is NMRA down ८.०७%?
Dive Deeper
NMRA:NASDAQ
Neumora Therapeutics Inc
US$ ०.४४
-८.०७%
(-०.०३८) 1D
US$ ०.४४
+०.९८% (+०.००४३)
After hours
Closed: अक्टोबर १२, १६:००:०० GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NMRA...
Open
US$ ०.४८
High
US$ ०.४८
Low
US$ ०.४४
Mkt. cap
८.१४ करोड
Avg. vol.
१७.३५ लाख
Volume
१२.११ लाख
52-wk high
US$ ३.६५
52-wk low
US$ ०.४४
EPS
-US$ १.२३
Beta
२.९५
Shares outstanding
१८.७९ करोड
No. of employees
६३
Open
US$ ०.४८
High
US$ ०.४८
Low
US$ ०.४४
Mkt. cap
८.१४ करोड
Avg. vol.
१७.३५ लाख
Volume
१२.११ लाख
52-wk high
US$ ३.६५
52-wk low
US$ ०.४४
EPS
-US$ १.२३
Beta
२.९५
Shares outstanding
१८.७९ करोड
No. of employees
६३
News stories
From web sources and news partners
About Neumora Therapeutics Inc
CEO-
Employees६३
Founded२०१९
HeadquartersWatertown, म्यासेचुसेट्स, संयुक्त राज्य अमेरिका
Sector-
Websiteneumoratx.com
Analyst ratings
Based on 5 analysts giving stock ratings to NMRA in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for NMRA in the last 3 months.
Highest
Current US$ ०.४४
US$ ७.०० (+१,५००.७३%)
Average
US$ ५.२५ (+१,१००.५५%)
Lowest
US$ ४.०० (+८१४.७०%)
Analyst
Recommendation
Action
Price target
Projected
Date
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
US$ ७.००
+१,५००.७%
08/24/2026
Graig Suvannavejh
Mizuho Securities
Buy
Reiterated
US$ ४.००
+८१४.७%
08/17/2026
Ami Fadia
Needham
Buy
Reiterated
US$ ५.००
+१,०४३.४%
08/14/2026
Myles Minter
William Blair
Buy
Reiterated
-
-
08/14/2026
Brian Abrahams
RBC Capital
Buy
Maintained
US$ ५.००
+१,०४३.४%
08/14/2026
Tessa Romero
J.P. Morgan
Sell
Maintained
-
-
05/26/2026
Paul Matteis
Stifel Nicolaus
Hold
Maintained
US$ ३.००
+५८६%
05/12/2026
Yatin Suneja
Guggenheim
Buy
Maintained
US$ १४.००
+३,१०१.५%
05/07/2026
Last report
२०२६ अगस्ट १४
Fiscal period
Q2 2026
-US$ ०.२३ / -US$ ०.२४
+५.३४%beat
Revenue / Est. (USD)
- / ०.००
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
४.०५ करोड
४.४७ करोड
३.८६ करोड
२.९३ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
१.२२ करोड
१.३८ करोड
१.४३ करोड
१.२९ करोड
Operating expense
५.२७ करोड
५.८५ करोड
५.२९ करोड
४.२२ करोड
Total operating expenses
५.२७ करोड
५.८५ करोड
५.२९ करोड
४.२२ करोड
Operating income
-५.२७ करोड
-५.८५ करोड
-५.२९ करोड
-४.२२ करोड
Other non operating income
७.०० हजार
-२.६९ लाख
५९.०० हजार
-७.०० हजार
EBT including unusual items
-५.६८ करोड
-५.९४ करोड
-५.३४ करोड
-४.३१ करोड
EBT excluding unusual items
-५.१८ करोड
-५.९४ करोड
-५.३४ करोड
-४.३१ करोड
Income tax expense
-
-
३०.०० हजार
-
Effective tax rate
-
-
-०.०६%
-
Other operating expenses
-
-
-
-
Net income
-५.६८ करोड
-५.९४ करोड
-५.३५ करोड
-४.३१ करोड
Net profit margin
-
-
-
-
Earnings per share
-०.३५
-०.३५
-०.३०
-०.२३
Interest and investment income
१६.८५ लाख
१३.३५ लाख
१२.३१ लाख
९.३५ लाख
Interest expense
-७.४७ लाख
-२०.३६ लाख
-१८.५४ लाख
-१८.२० लाख
Net interest expenses
९.३८ लाख
-७.०१ लाख
-६.२३ लाख
-८.८५ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-५.२७ करोड
-५.८५ करोड
-५.२९ करोड
-४.२२ करोड
Gain or loss from assets sale
-६२.०० हजार
२.६४ लाख
-७१.०० हजार
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू